Skip to main content
. 2022 Apr 30;34(2):95–108. doi: 10.21147/j.issn.1000-9604.2022.02.04

Figure S5.

Figure S5

Comparison of PFS and OS curves between CTCWT1+ and CTCWT1− patients. (A) Median PFS of CTCWT1+ and CTCWT1− patients was 42.0 and 35.0 months, respectively, but there was no statistical difference (HR=0.869; 95% CI: 0.546−1.384; P=0.308); (B) OS of CTCWT1+ and CTCWT1− patients was not statistically different (HR=0.735; 95% CI: 0.391−1.381; P=0.201). PFS, progression-free survival; OS, overall survival; CTC, circulating tumor cell; HR, hazard ratio; 95% CI, 95% confidence interval.